Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs (Q36570803)

15 August 2017

1 reference

title

Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs (English)

1 reference

15 August 2017

0 references

1 reference

Laine L

1

1 reference

15 August 2017

Smith R

2

1 reference

15 August 2017

Min K

3

1 reference

15 August 2017

Chen C

4

1 reference

15 August 2017

Dubois RW

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Alimentary Pharmacology & Therapeutics

15 August 2017

published in

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

751-767

1 reference

NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Visible small-intestinal mucosal injury in chronic NSAID users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

In vivo Influence of Nicotine on Human Basal and NSAID-induced Gut Barrier Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Risk factors for hospitalized upper or lower gastrointestinal tract bleeding in treated hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Gastro-intestinal permeability is increased in patients with limited systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Evidence of aspirin use in both upper and lower gastrointestinal perforation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Glucose and citrate reduce the permeability changes caused by indomethacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Are prostaglandins cytoprotective in the human large intestine? The effect of indomethacin on rectal mucosal function and prostaglandin E2 release in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03043.X

10.1111/J.1365-2036.2006.03043.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference